NORAD knockdown enhances the effect of the combination of the immune checkpoint inhibitor PD-1 and RT in the treatment of ESCC [172], but only a small number of ESCC patients have benefited. This evidence concerns the gene NORAD and esophageal squamous cell carcinoma.